Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.53 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.53 |
| ▸ | PNP | P00491 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.47 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.47 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | ADA | P00813 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL8840690 | 0.99 | ADRB1 (0.52) | ADRB1DNMT1PNPLMNATP53 | |
| SCHEMBL16348683 | 0.88 | PIM1 (0.48) | ADRB1DNMT1PNPLMNATP53 | |
| SCHEMBL2216449 | 0.87 | ADRB1 (0.53) | ADRB1DNMT1PNPLMNATP53 | |
| SCHEMBL8840703 | 0.87 | PIM1 (0.47) | ADRB1DNMT1PNPLMNATP53 | |
| SCHEMBL5317002 | 0.83 | TP53 (0.50) | DNMT1LMNATP53HTTSMN1; SMN2 | |
| SCHEMBL40771 | 0.83 | TP53 (0.50) | DNMT1LMNATP53HTTSMN1; SMN2 | |
| SCHEMBL1021989 | 0.83 | DNMT1 (0.49) | ADRB1DNMT1PNPLMNATP53 | |
| SCHEMBL16348679 | 0.81 | TP53 (0.41) | DNMT1LMNATP53HTTSMN1; SMN2 | |
| SCHEMBL8840692 | 0.81 | ADRB1 (0.33) | ADRB1DNMT1PNPLMNATP53 | |
| SCHEMBL1062371 | 0.80 | POLB (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240200118-A1 | COMPOSITIONS AND METHODS FOR OPTIMIZING TROPISM OF DELIVERY SYSTEMS FOR RNA | RENAGADE THERAPEUTICS MANAGEMENT INC. | 2024-06-20 | — | — | US | disclosed |
| US-20230037279-A9 | METHOD FOR DIAGNOSING DISEASES USING MULTIPLEX FLUORESCENCE AND SEQUENCING | MultiplexDX, s.r.o. (SK) | 2023-02-02 | — | — | US | disclosed |
| US-20220002812-A1 | METHOD FOR DIAGNOSING DISEASES USING MULTIPLEX FLUORESCENCE AND SEQUENCING | MULTIPLEXDX S R O (SK) | 2022-01-06 | — | — | US | disclosed |
| EP-3775277-A1 | METHOD FOR DIAGNOSING DISEASES USING MULTIPLEX FLUORESCENCE AND SEQUENCING | MultiplexDX, s.r.o. (SK) | 2021-02-17 | — | — | EP | disclosed |
| WO-2020070325-A1 | METHOD FOR DIAGNOSING DISEASES USING MULTIPLEX FLUORESCENCE AND SEQUENCING | MULTIPLEX DX (SK) | 2020-04-09 | — | — | WO | disclosed |
| WO-2017097973-A1 | MODIFIED NUCLEOSIDES | UNIVERSITAET KONSTANZ (DE) | 2017-06-15 | — | — | WO | disclosed |
| US-9605261-B2 | RNA synthesis—phosphoramidites for synthetic RNA in the reverse direction, and application in convenient introduction of ligands, chromophores and modifications of synthetic RNA at the 3′-end | CHEMGENES CORPORATION (US) | 2017-03-28 | — | — | US | disclosed |
| US-20150218557-A1 | RNA SYNTHESIS-PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, AND APPLICATION IN CONVENIENT INTRODUCTION OF LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA AT THE 3'-END | CHEMGENES CORPORATION | 2015-08-06 | — | — | US | disclosed |
| WO-2004058252-A2 | ANTI-CANCER AGENTS COMPRISING ALKB INHIBITORS AND ALKYLATING AGENTS | ISIS INNOVATION LIMITED (GB) | 2004-07-15 | — | — | WO | disclosed |
| EP-0929218-A4 | P2Y RECEPTOR ANTAGONISTS | UNIV NORTH CAROLINA (US) | 2001-05-16 | — | — | EP | disclosed |
| EP-0929218-A2 | P2Y RECEPTOR ANTAGONISTS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1999-07-21 | — | — | EP | disclosed |
| US-5773424-A | PARASITICIDE | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1998-06-30 | — | — | US | disclosed |
| WO-1998018430-A2 | P2Y RECEPTOR ANTAGONISTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1998-05-07 | — | — | WO | disclosed |
| EP-0540742-A1 | OLIGODEOXYRIBONUCLEOTIDES | Shudo, Koichi, Prof. Dr. (JP) | 1993-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240200118-A1 | COMPOSITIONS AND METHODS FOR OPTIMIZING TROPISM OF DELIVERY SYSTEMS FOR RNA | NSUN3, PHAX, RNGTT | ADRB1 3441/4885DNMT1 3245/4885PNP 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.